Intrathecal baclofen therapy in patients with severe spasticity
- PMID: 17691373
- DOI: 10.1007/978-3-211-33079-1_23
Intrathecal baclofen therapy in patients with severe spasticity
Abstract
Spasticity has been described as "a motor disorder, characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyper-excitability of the stretch reflex as one component of the upper motor neuron syndrome". In patients with complete spinal cord lesions, severe untreatable spasticity can make movement, sitting and hygiene difficult or impossible while it may alter gait and personal care in patients with partial lesions. From a clinical point of view, it is useful to distinguish spinal cord spasticity from supraspinal spasticity. Traditionally, the Ashworth scale is the most widely used to quantify the tone of single muscles. In order to quantify hypereflexia, the Reflex Scale is also used. In the spinal spasticity which is characterized by spasms, the Spasm Frequency Scale is useful in order to monitor their frequency. Initially, management of spasticity is based on non-invasive treatments that later become more invasive. The first approach. the conservative treatment, usually includes elimination of the nociceptive stimuli, rehabilitative therapy (physical and occupational), orthopaedic prostheses and plaster corsets. These treatments, do not resolve spasticity in about 33% of cases. In these severe cases, more invasive procedures such as muscle infiltrations with botulin toxin and intrathecal baclofen infusion can be used.
Similar articles
-
The effect of intrathecal baclofen on muscle co-contraction in children with spasticity of cerebral origin.Pediatr Neurosurg. 2002 Nov;37(5):225-30. doi: 10.1159/000066212. Pediatr Neurosurg. 2002. PMID: 12411712 Clinical Trial.
-
Efficacy of intrathecal baclofen delivery in the management of severe spasticity in upper motor neuron syndrome.Acta Neurochir Suppl. 2007;97(Pt 1):205-11. doi: 10.1007/978-3-211-33079-1_28. Acta Neurochir Suppl. 2007. PMID: 17691378 Review.
-
Intrathecal baclofen for spasticity in primary lateral sclerosis.J Neurol. 2005 Jun;252(6):740-1. doi: 10.1007/s00415-005-0746-7. Epub 2005 Mar 29. J Neurol. 2005. PMID: 15789133 No abstract available.
-
Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study.Acta Neurochir Suppl. 2007;97(Pt 1):181-4. doi: 10.1007/978-3-211-33079-1_24. Acta Neurochir Suppl. 2007. PMID: 17691374 Clinical Trial.
-
Intrathecal baclofen for the treatment of spasticity.Acta Neurochir Suppl. 2007;97(Pt 1):185-8. doi: 10.1007/978-3-211-33079-1_25. Acta Neurochir Suppl. 2007. PMID: 17691375 Review.
Cited by
-
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.ISRN Neurol. 2012;2012:802649. doi: 10.5402/2012/802649. Epub 2012 Aug 7. ISRN Neurol. 2012. PMID: 22928118 Free PMC article.
-
Conference Abstracts "Bridges in Rehabilitation" of the 2nd Physical Medicine and Rehabilitation Department, National Rehabilitation Center EKA (Ethniko Kentro Apokatastasis) 14-15 December 2024, National Rehabilitation Center EKA, Ilion, Athens, Greece.J Frailty Sarcopenia Falls. 2025 Jun 1;10(2):114-127. doi: 10.22540/JFSF-10-114. eCollection 2025 Jun. J Frailty Sarcopenia Falls. 2025. PMID: 40487150 Free PMC article. No abstract available.